ABSTRACT - 596395 The disclosure relates to a solid preparation comprising (i) compound selected from the group consisting of 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid, and 2-ethoxy-1-[[2'-(4,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid or a salt thereof, (ii) a sugar alcohol selected from mannitol, sorbitol or erythritol, (iii) a dihydropyridine compound having calcium antagonistic activity, which is selected from azelnidipine, amlodipine, aranidipine, efonidipine, cilnidipine, nicardipine, nisoldipine, nitrendipine, nifedipine, nilvadipine, barnidipine, felodipine, benidipine, manidipine or a salt thereof. These solid preparations are stable and have an appropriately controlled dissolution rate of the active ingredient in the gastrointestinal tract.
